We have analyzed the in vitro activities of pyronaridine and methylene blue against 59 Plasmodium falciparum isolates from Kenya in association with polymorphisms in Pfcrt (codon 76), Pfmdr1 (codon 86), and Pfnhe (full sequence). The median inhibitory concentrations that kill 50% of parasites were 13.5 and 3.3 nM for pyronaridine and methylene blue, respectively. Their activities were not associated with polymorphisms in these genes. The drugs' high in vitro activities indicate that they would be efficacious against Kenyan isolates in vivo.
arum field isolates against PRN and MB. As comparators, we have included the already-published data on the same isolates against CQ, LM, PIQ and QN, AQ, DEAQ, and DHA (13) (14) (15) 27) . Median IC 50 s for PRN and MB against the multidrug-resistant strain V1S were 12 and 1 nM, respectively, and values for the fully sensitive strain 3D7 were 8 and 2 nM, respectively.
Against field isolates, median IC 50 s for PRN and MB were 13.5 nM (interquartile range [IQR], 4.6 to 31.5) and 3.3 nM (IQR, 1.7 to 8.0), respectively. Values for CQ, LM, PIQ, and DHA are presented in Fig. 1 , and those for QN, AQ, and DEAQ were 141.1 nM (IQR, 50.9 to 268.2), 7.8 nM (IQR, 5.4 to 8.6), and 8.5 nM (IQR, 7.4 to 16.9), respectively. PRN was more active than CQ, LM, and PIQ; MB was more active than all these aforementioned drugs, except DHA. Our data are in line with previous reports showing the high potency of PRN in vitro against isolates from Cameroon (26), Senegal (22) , and Gabon (9) .
PRN was used up to the 1990s as a monotherapy for the treatment of malaria in China (4) and was tested in Cameroon with encouraging results (25) . Its combination with ART (Pyramax) has proven efficacious in many African countries, including Kenya (24, 31) , in line with our in vitro data. PRN has also been proven potent in vitro against P. falciparum isolates from Southeast Asia, a known area of multidrug resistance (23) . Interestingly, PRN is also active against Plasmodium vivax in vitro (23) , and recently, the in vivo efficacy of PRN-ART against P. vivax has been shown, making this combination a potential drug for the treatment of P. vivax infection as well (18) .
MB has proven efficacious in African countries, mainly in Burkina Faso (3, 10, 11, 32) , and has gametocytocidal properties; thus, it could be part of treatment combinations to reduce transmission of P. falciparum (6) . Our data show that MB is active in vitro, in line with 2 previous studies using African parasites (1, 17) .
Thus, this drug would also be efficacious against the Kenyan parasite population.
We also investigated the role of polymorphisms within Pfcrt-76, Pfmdr1-86, and Pfnhe. PRN is more active against parasites harboring the wild-type sequence than against those harboring the mutant sequence at the Pfcrt-76 codon (IC 50 s of 6 versus 20 nM) and at the Pfmdr1-86 codon (IC 50 s of 7 versus 19 nM); however, these differences were not significant (P Ͼ 0.05). This lack of association has also been reported elsewhere (19) .
Data for MB showed that its activity was not affected by polymorphisms in Pfcrt-76 and Pfmdr1-86. Likewise, no change was observed between the activity of PRN and MB and polymorphisms in Pfnhe, a gene associated with QN resistance (16) , in line with a previous report (17) .
We also analyzed the correlation between PRN and MB in vitro activities and those of CQ, LM, PIQ, AQ, DEAQ, QN, and DHA. PRN activity was significantly correlated with those of the quinolone-based drugs PIQ, AQ, DEAQ, and QN but not with CQs (Table 1) . PRN in vitro activity was found to correlate with CQ, AQ, or QN in some studies (20, 21, 23) but not in others (9, 19) . We did not find a correlation between PRN and DHA activities, as reported previously (9) . However, a significant correlation between PRN and ART was found (19, 23) . Since artemisinin resistance is now emerging (7), it is important to establish the extent to which this resistance may affect PRN activity. We observed a significant correlation between MB and CQ, LM, DEAQ, QN, and DHA, while no association was found between MB and PIQ and between QN and PRN. To the best of our knowledge, only one study addressed this correlation: MB activity was not correlated with CQ, QN, DEAQ, LM, and DHA (17) . Clearly, further investigations are needed to define the relationship between the in vitro activities of MB and other antimalarials.
We have provided the first evidence of the in vitro activity of PRN and MB against isolates from Kenya. The high in vitro activities of these 2 drugs are in line with data reported in other parts of Africa and also confirm (at least in the case of PRN) the reported efficacy of PRN-ART in Kenya. 
